{"filings":[{"id":2024077,"accession_number":"0001609550-26-000045","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-08-03T20:03:40+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q2 revenue down 7.6% to $200.6M; raises FY2026 guidance; announces Project Horizon restructuring","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $200.6M (-7.6% YoY); diluted EPS $0.01, adjusted diluted EPS $0.14.","Gross margin 85.5% (+150 bps); operating cash flow $23.2M vs $2.7M prior year.","Raised FY2026 revenue guidance to $835M-$875M; adjusted diluted EPS guidance $1.05-$1.45.","Announced Project Horizon restructuring to generate $30M annualized growth investment capacity; expects $20M-$25M pre-tax charges.","Cash and investments $415.2M as of June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1856596,"accession_number":"0001609550-26-000041","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-07-24T20:01:24+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inspire Medical appoints Michael H. Carrel to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael H. Carrel, CEO of AtriCure (ATRC), appointed to Inspire Medical's Board as Class III director, effective July 20, 2026.","Carrel will serve on Organization and Compensation Committee and Quality, Product Supply and Technology Committee.","He receives standard non-employee director compensation: $55k annual cash retainer, $7.5k per committee, initial RSU award of $300k vesting over 3 years, annual RSU of $200k.","Carrel's background includes leadership at AtriCure, Vital Images, Zamba, and board service at Axonics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1785036,"accession_number":"0001609550-26-000038","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-07-22T12:02:09+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inspire Medical board member Casey Tansey to retire effective July 30, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Casey Tansey notified the Board of his retirement effective July 30, 2026, and will not stand for re-election at the 2027 Annual Meeting.","Tansey served on the Board for over 18 years, representing U.S. Venture Partners and leading the Series A financing in 2007.","Retirement is not due to any disagreement with the Company's operations, policies, or practices.","Company expects to announce a new Director to replace Mr. Tansey in the near future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1285756,"accession_number":"0001609550-26-000035","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-06-26T10:41:31+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire Medical to present at investor meetings in June 2026; materials available online","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company is participating in investor and analyst meetings in June 2026.","Presentation materials furnished as Exhibit 99.1 and posted on IR website.","No financial results or material new disclosures in the 8-K text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94069,"accession_number":"0001609550-26-000026","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Inspire Medical shareholders approve declassification, 2.6M-share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved phasing out classified board; all directors to be elected annually starting 2029.","Approved amendment of 2018 Incentive Award Plan: adds 2.6M shares (total authorized 9.9M), removes evergreen, extends term to 2036.","Elected Class II directors: Ellis, Melenikiotou, Mead Jr. with >17M votes for each.","Ratified Ernst & Young as auditor (25.1M for); approved say-on-pay (22.5M for) with 1-year frequency (22.9M for).","Proposal 5 (declassification) passed with 23.1M for; Proposal 6 (equity plan) passed with 14.3M for; broker non-votes not counted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94068,"accession_number":"0001609550-26-000021","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q1 revenue up 1.6% to $204.6M; guides FY2026 revenue down 4-10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $(0.39); adjusted diluted EPS $0.10; operating cash flow $12.8M.","Coding/reimbursement uncertainty for Inspire V and WISeR program disrupted Q1.","FY2026 revenue guidance revised to $825M-$875M (decline 4-10% vs 2025).","Adjusted operating margin guidance of 2%-4%; adjusted diluted EPS $0.75-$1.25.","Expects coding challenges to persist through 2026, with growth returning in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":204583000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106174,"accession_number":"0001609550-26-000012","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","5.03","7.01","9.01"],"status":"ready","headline":"Inspire Q4 rev $269M (+12%), EPS $4.66; FY26 outlook lowered on coding change","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $269.1M (+12%); GAAP diluted EPS $4.66; adjusted EPS $1.65.","Full year revenue $912M (+14%); operating cash flow $117M; share repurchases $175M.","FY2026 revenue guidance revised to $950M-$1.0B (4-10% growth); adjusted EPS $1.85-$2.35.","Inspire V procedure coding changed to CPT 64582 with -52 modifier, reducing physician fees; company disappointed.","Board proposes declassification and removal of for-cause removal; effective upon shareholder approval at 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":4.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":911981000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106173,"accession_number":"0001609550-26-000006","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical posts preliminary Q4 rev ~$269M (+12% YoY); 2026 guidance $1,003-1,013M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 revenue ~$269M, up 12% YoY; full-year 2025 revenue ~$912M, up 14% YoY.","Initial FY 2026 revenue guidance of $1,003M-$1,013M, implying 10-11% growth over 2025.","Appointed Matt Osberg as EVP and CFO, start Jan 19, 2026; base salary $650k, sign-on $600k, equity awards $3M.","Rick Buchholz steps down as CFO, serves as interim CFO through filing of 2025 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":4.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":911981000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122455,"accession_number":"0001609550-25-000055","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Inspire Medical Systems expects $90M-$100M tax benefit from valuation allowance release","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company disclosed expectation to release a significant portion of valuation allowance on U.S. deferred tax assets.","Estimated income tax benefit of $90 million to $100 million for fiscal year 2025.","Diluted earnings per share expected to increase by approximately $3.00 to $3.30.","Disclosure made on November 6, 2025, and filed on November 17, 2025.","The benefit will be recorded in the fourth quarter of fiscal 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122454,"accession_number":"0001609550-25-000052","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q3 revenue $224.5M (+10% YoY); net income down; FY25 EPS guidance raised to $0.90-$1.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $224.5M in Q3 2025, up 10% from $203.2M a year ago; U.S. revenue $214.4M (+9%), OUS revenue $10.1M (+37%).","Gross margin 85.8% vs 84.1% YoY, driven by higher volume and Inspire V mix with lower COGS.","Net income $9.9M ($0.34 diluted EPS) vs $18.5M ($0.60) prior year; adjusted diluted EPS $0.38.","FY2025 revenue guidance reaffirmed $900M-$910M (12-13% growth); EPS guidance raised to $0.90-$1.00 from $0.40-$0.50.","Completed $50M in share repurchases; Q3 operating cash flow $68.5M; cash & investments $410.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":642904000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122453,"accession_number":"0001609550-25-000046","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire V clinical data shows superior efficacy, adherence, and reduced surgical times; AHI cut from 34.4 to 8.3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Singapore study (44 patients): Inspire V IPOP 87.1% vs Inspire IV 79.4%, exceeding non-inferiority margin of 4.6%.","Median AHI reduced from 34.4 to 8.3 events/hour at 6 months for 37 Singapore patients.","US limited market release (101 patients): no serious adverse events; 100% therapy usage at 60 days; average adherence 6.8 hrs/night.","AHI for first 34 US patients dropped from 30 to 4.5 events/hour; average stimulation amplitude 1.7V.","20% reduction in surgical times; average implant time 34.5 minutes at one site; new internal respiratory sensing eliminates pressure lead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139149,"accession_number":"0001609550-25-000040","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Systems CFO Rick Buchholz to step down by Dec 31, 2025; 2025 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Rick Buchholz resigns effective Dec 31, 2025, will remain in advisory role through Feb 28, 2026.","Transition agreement provides 9 months base salary and COBRA; departure not due to any dispute.","Company has begun search for new CFO with assistance of an executive search firm.","Reaffirms FY 2025 guidance: revenue $900-910M, gross margin 84-86%, diluted EPS $0.40-$0.50."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139148,"accession_number":"0001609550-25-000035","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inspire Medical Systems board authorizes $200M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $200M of common stock.","Program expires August 7, 2027, unless extended or terminated earlier.","CEO cites financial strength and confidence in growth as rationale.","Company states stock is undervalued and addressable market lightly penetrated.","Purchases may occur via open market or private transactions; no obligation to buy specific number."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139147,"accession_number":"0001609550-25-000030","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q2 net loss $3.6M, cuts FY 2025 revenue guidance to $900-910M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $217.1M (+11% YoY), net loss $3.6M vs prior year net income $9.8M.","Adjusted diluted EPS $0.45; GAAP diluted loss per share $0.12.","FY 2025 revenue guidance cut to $900-910M (prior $940-955M); EPS cut to $0.40-0.50 from $2.20-2.30.","Full U.S. launch of Inspire V neurostimulation system initiated.","EVP Randall Ban to retire on January 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":418403000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156689,"accession_number":"0001609550-25-000025","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire Medical Systems files investor presentation for June 2025 meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company will participate in investor and analyst meetings in June 2025.","Presentation materials furnished as Exhibit 99.1 but no specific content provided in filing.","No financial results, guidance, or material events disclosed in the 8-K body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156688,"accession_number":"0001609550-25-000019","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inspire Medical stockholders approve all proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class I director nominees elected: Burks (20.5M for), Herbert (21.1M for), McCormick (19.9M for).","Ratification of Ernst & Young as auditor for 2025: 28.4M for, 364K against, 8.4K abstain.","Advisory vote on executive compensation approved: 25.0M for, 1.86M against, 33K abstain (broker non-votes 1.82M).","Approximately 96.53% of outstanding shares (28.7M) represented at May 1, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156687,"accession_number":"0001609550-25-000018","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q1 rev $201.3M (+23% YoY), EPS $0.10; raises FY EPS guidance to $2.20-$2.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $201.3M, up 23% YoY; U.S. revenue $193.6M (+24%), OUS $7.7M (-6%).","Net income $3.0M (diluted EPS $0.10) vs net loss $10.0M ($0.34 loss) in Q1 2024.","Adjusted EBITDA $33.2M, up from $11.9M; operating loss improved 90% to $1.5M.","Surpassed 100,000 patients on Inspire therapy; Inspire V system launch starting in U.S. May 2025.","FY 2025 revenue guidance maintained $940-955M; EPS guidance raised to $2.20-$2.30 (from $2.10-$2.20)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":201317000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175100,"accession_number":"0001609550-25-000009","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q4 revenue $239.7M (+25% YoY); EPS $1.15; guides FY2025 rev $940-955M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $239.7M (+25% YoY); net income $35.2M, diluted EPS $1.15 vs $0.49 prior year.","Full year 2024 revenue $802.8M (+28% YoY); net income $53.5M ($1.75 diluted EPS) vs net loss in 2023.","FY2025 guidance: revenue $940-955M (17-19% growth); diluted EPS $2.10-$2.20.","Added 72 U.S. centers in Q4 (total 1,435); U.S. sales territories now 335; over 90,000 patients treated.","Initiated $75M accelerated share repurchase program; operating cash flow $130.2M for full year."],"consensus_eps_estimate":null,"consensus_eps_actual":1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":802804000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175099,"accession_number":"0001609550-25-000003","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical reports Q4 revenue ~$239.7M (+25% YoY); issues 2025 guidance $940-955M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue ~$239.5-239.7M, up 25% YoY; full year 2024 revenue ~$802.6-802.8M, up 28% YoY.","Initial FY2025 revenue guidance of $940-955M, representing 17-19% growth over FY2024.","Soft launch of Inspire V neurostimulator with over 40 implants completed in Singapore and U.S.","Appointed Jason Kelly as Chief Manufacturing and Quality Officer effective Jan 20, 2025; Dr. Sparks, CMO, left.","Activated 72 new U.S. centers in Q4 (total 1,435); 12 new sales territories (total 335)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":802804000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192048,"accession_number":"0001609550-24-000055","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Inspire Medical enters $75M accelerated share repurchase with Goldman Sachs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ASR agreement for $75M repurchase under existing $150M buyback program authorized by Board.","Payment of $75M on Nov 12; initial delivery of shares worth 80% of repurchase price based on Nov 8 close.","Final settlement in Q1 2025; Inspire may receive additional shares or pay cash to GS&Co. under terms.","ASR contains standard provisions for adjustments, early termination, and representations by both parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192047,"accession_number":"0001609550-24-000050","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q3 revenue $203.2M (+33% YoY), EPS $0.60 vs loss, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $203.2M, up 33% YoY; U.S. revenue $195.8M (+33%), OUS $7.4M (+27%).","Operating income $14.3M vs loss $13.5M; net income $18.5M, diluted EPS $0.60 vs loss $0.29.","Raises FY 2024 revenue guidance to $793-798M (27-28% growth) and EPS guidance to $1.20-1.40.","Activated 66 new U.S. centers (total 1,371); created 13 new sales territories (total 323).","Received FDA approval for Inspire V neurostimulation system; gross margin steady at 84.1%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":563086000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208533,"accession_number":"0001609550-24-000042","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Inspire Q2 revenue $195.9M (+30% YoY), EPS $0.32; raises FY guide, authorizes $150M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $195.9M (30% YoY), net income $9.8M vs loss $12.0M; diluted EPS $0.32 vs ($0.41).","FY 2024 revenue guidance raised to $788-798M (26-28% growth); EPS guidance raised to $0.60-0.80 from $0.10-0.20.","Board authorized $150M share repurchase program, first in company history, expiring August 5, 2026.","Received FDA approval for Inspire V neurostimulation system and EU MDR CE Mark for full-body MRI compatibility.","Activated 81 new U.S. centers in Q2 (total 1,316) and added 12 sales territories (total 310)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":359895000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208532,"accession_number":"0001609550-24-000036","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inspire Medical receives FDA approval for next-gen Inspire V neurostimulation system","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Inspire V system including next-generation neurostimulator, Bluetooth patient remote, and physician programmer.","Targets soft launch in late 2024 and full commercial launch in 2025.","Company focusing on operational readiness: product manufacturing and inventory levels for U.S. launch.","CEO cites FDA approval as a key milestone for Inspire therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208531,"accession_number":"0001609550-24-000034","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inspire Medical pre-announces Q2 revenue $195.9M (+30% YoY), raises 2024 guidance to $788-798M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $195.9M, up 30% YoY; US revenue $187.8M (+30%), OUS $8.1M (+27%).","Full-year 2024 revenue guidance raised to $788-798M, up $13M from prior $775-785M range.","Management cites strong execution and sequential US revenue growth acceleration.","Complete Q2 results and earnings call scheduled for August 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":359895000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208530,"accession_number":"0001609550-24-000032","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inspire Medical COO Philip Ebeling resigns effective Aug 9 to become CEO at private cardiology device firm","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philip J. Ebeling notified Inspire Medical on July 18, 2024 of his resignation as COO, effective Aug 9, 2024.","Ebeling leaves to become President and CEO of a private medical device company in the cardiology space.","Resignation was not due to any disagreement with the Company or its management.","Ebeling joined Inspire Medical in June 2020; the Company will conduct a search for a new COO with an executive search firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226230,"accession_number":"0001609550-24-000028","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inspire Medical shareholders elect directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class III director nominees elected: Broader (26.3M for), Dr. Curet (23.5M for), Tansey (26.1M for).","Ratification of Ernst & Young as independent auditor for FY2024 with 27.5M votes for, 833K against.","Advisory vote on named executive officer compensation approved with 25.9M for, 670K against.","28.3M shares represented, 95.44% of outstanding common stock; 1.57M broker non-votes on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226229,"accession_number":"0001609550-24-000024","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q1 revenue $164M (+28% YoY); raises FY2024 guidance, expects full-year profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $164.0M, up 28% YoY; net loss narrowed to $10.0M ($0.34/share) from $15.4M.","U.S. revenue $155.8M (+25% YoY); OUS revenue $8.2M (+141%); gross margin 84.9% vs 84.4%.","FY2024 revenue guidance raised to $783-793M (25-27% growth); first-time diluted EPS guidance $0.10-$0.20.","Added 66 new U.S. centers (total 1,246) and 11 new sales territories (total 298) in Q1.","Ended Q1 with $469.2M cash; expects full-year 2024 profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":164010000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245296,"accession_number":"0001609550-24-000013","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q4 revenue $192.5M (+40%), first net income quarter $14.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $192.5M (+40% YoY); full year $624.8M (+53%). U.S. revenue $189.4M (+41%).","Q4 net income $14.8M (diluted EPS $0.49) vs $3.2M ($0.10) a year ago; FY net loss improved 53% to $21.2M.","Gross margin 85.4% in Q4 vs 83.9% a year ago; FY 2024 guidance 83%-85%.","Reaffirms FY 2024 revenue guidance of $775M-$785M (24-26% growth).","Added 78 new U.S. implanting centers in Q4 (total 1,180) and 13 sales territories (total 287)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":624799000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245295,"accession_number":"0001609550-24-000011","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inspire Medical CEO Tim Herbert to succeed Marilyn Carlson Nelson as Board Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marilyn Carlson Nelson will retire as Board Chair at the May 2, 2024 annual meeting; departure not due to any disagreement.","CEO Timothy P. Herbert appointed as Board Chair, effective after the annual meeting.","Gary L. Ellis appointed as Lead Independent Director; he previously served as Medtronic CFO.","Herbert founded Inspire and has served as President & CEO since May 2007."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245294,"accession_number":"0001609550-24-000008","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inspire Medical board member Jerry C. Griffin retiring after 16 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Griffin will retire effective at the conclusion of the 2024 Annual Meeting on May 2, 2024.","He served on the Board since 2008, most recently on the Nominating and Corporate Governance Committee.","Retirement not due to any disagreement with the Company on operations, policies, or practices.","In December 2023, the Board appointed Myriam J. Curet, M.D. (EVP & CMO of Intuitive Surgical) as a new director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245293,"accession_number":"0001609550-24-000004","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Systems Q4 preliminary revenue ~$192.4M (+40% YoY); FY2024 guidance $775-785M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue expected $192.3-192.5M, ~40% increase over Q4 2022.","FY2023 revenue expected $624.6-624.8M, ~53% increase over FY2022.","Added 78 new U.S. centers in Q4, total 1,180; 13 new sales territories, total 287.","Initial FY2024 revenue guidance $775-785M, 24-26% growth over FY2023.","Company expects to report a profitable Q4 when full results are released Feb 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":624799000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262742,"accession_number":"0001104659-23-129879","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inspire Medical appoints Intuitive Surgical executive Myriam Curet to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Myriam J. Curet, M.D. as independent director, effective Dec 21, 2023.","Dr. Curet is EVP & Chief Medical Officer at Intuitive Surgical and Professor of Surgery at Stanford.","She will serve on the Nominating and Corporate Governance Committee.","Initial RSU award valued at $270,000 (3-year vest); annual cash retainer $50,000 plus $7,500 committee fee.","She adds expertise in medical device R&D, regulatory affairs, and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262741,"accession_number":"0001609550-23-000065","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire Medical posts Q3 2023 investor presentation for Nov/Dec meetings; no new material facts disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company will attend multiple investor meetings in November and December 2023.","Presentation titled 'q32023presentation-xfina' is now available on the IR website.","Filing does not contain financial results, guidance changes, or other material updates.","Exhibit text in this filing is truncated; full presentation content is not provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262740,"accession_number":"0001609550-23-000061","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inspire Medical Q3 revenue $153.3M (+40% YoY); raises FY2023 guidance to $608-612M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $8.5M ($0.29 per share) from $16.8M ($0.60) YoY.","U.S. revenue $147.5M (+39%); OUS revenue $5.8M (+99%). Gross margin improved to 84.1%.","Added 62 new U.S. implant centers (total 1,107) and 13 new sales territories (total 274).","Surpassed 50,000 patients treated with Inspire therapy globally.","FY2023 revenue guidance raised to $608-612M (49-50% growth); gross margin guidance maintained at 83-85%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":432291000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279927,"accession_number":"0001609550-23-000054","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire Medical furnishes generic investor presentation; no new financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company participating in investor and analyst meetings in August and September 2023.","Presentation furnished as Exhibit 99.1; no specific financial results or guidance disclosed in filing.","No material updates on revenue, product pipeline, or operational performance included in the exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279926,"accession_number":"0001609550-23-000049","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Inspire Med: Q2 rev $151.1M (+65% YoY), raises FY2023 guidance to $600-610M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $151.1M, up 65% YoY; U.S. rev $144.7M (+65%), OUS $6.3M (+81%).","Net loss improved to $12.0M from $14.5M; diluted EPS -$0.41 vs -$0.53.","Full-year 2023 revenue guidance raised to $600-610M (prior $580-590M). Maintains gross margin 83-85%.","FDA approved expanded AHI indication (up to 100 events/hr) and BMI labeling raise to 40; SleepSync programmer approved.","Appointed Charisse Y. Sparks, M.D. as CMO, effective July 27; she resigned from board."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":278989000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298424,"accession_number":"0001609550-23-000040","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire Medical presents at Wells Fargo Spotlight; highlights 41,000 procedures and SleepSync platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 41,000 Inspire procedures completed to date; ADHERE registry has 4,800 enrollments at 62 centers.","Inspire SleepSync digital platform aims to improve patient engagement and reduce time-to-implant.","U.S. market opportunity for Inspire estimated at ~$10 billion based on CPAP non-compliance and anatomy eligibility.","Presentation includes updates on Inspire V neurostimulator and PREDICTOR study to replace DISE.","No new financial guidance or material changes disclosed in the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298423,"accession_number":"0001609550-23-000038","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inspire Medical Systems stockholders elect directors, ratify auditor, approve exec compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four Class II director nominees elected; Gary L. Ellis received 9.6M withheld (37.6% of votes cast).","Ernst & Young ratified as independent auditor for 2023 with 26.3M for, 1.1M against.","Advisory say-on-pay passed with 22.7M for, 2.8M against, 1.9M broker non-votes.","Approximately 94% of outstanding shares (27.4M) represented at the April 27 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298422,"accession_number":"0001609550-23-000036","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire Medical Systems provides updated investor presentation for Q2 2023 meetings","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company to participate in multiple investor meetings during May and June 2023.","Presentation furnished as Exhibit 99.1, available on IR website; no new financial data disclosed.","No material business developments or changes announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298421,"accession_number":"0001609550-23-000032","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inspire Medical Q1 revenue up 84% to $127.9M; raises FY 2023 guidance to $580-590M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $127.9M (+84% YoY); U.S. revenue $124.5M (+87% YoY); gross margin 84.4%.","Net loss $15.4M ($0.53 diluted EPS) vs $16.7M ($0.61) prior-year; cash $452.1M.","Added 68 new U.S. centers (total 973) and 17 new sales territories (total 242) in Q1.","Raised FY 2023 revenue guidance to $580-590M from $560-570M; maintained gross margin 83-85%.","FDA approved therapy for pediatric Down syndrome (age 13+); finalized Belgium reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":127897000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318629,"accession_number":"0001609550-23-000017","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire Medical Systems releases Feb 2023 investor presentation; no material news disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company participating in investor meetings in February and March 2023.","Presentation furnished as Exhibit 99.1 and posted on Investor Relations page.","Available exhibit text truncated; no specific financial data or guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318628,"accession_number":"0001609550-23-000014","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inspire Medical posts first profitable quarter; Q4 revenue $137.9M (+76% YoY) and guides FY2023 $560-570M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net income $3.2M, diluted EPS $0.10, vs. loss of $2.4M in Q4 2021.","Q4 revenue $137.9M (76% YoY); U.S. revenue $134.3M (+78%), OUS revenue $3.6M (+28%).","Gross margin 83.9% in Q4, down from 85.8% due to inflation and supply chain costs.","Full year 2022 revenue $407.9M (+75% YoY); net loss $44.9M vs. $42.0M in 2021.","FY2023 revenue guidance $560-570M (37-40% growth); expects to add 52-56 new U.S. centers per quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":407856000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318627,"accession_number":"0001609550-23-000010","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire Medical presents at JP Morgan Healthcare Conference; no financial results disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company participating in investor meetings on January 9, 2023; presentation posted on IR website.","Presentation materials do not contain new financial guidance or material operational updates.","Exhibit 99.1 is a corporate overview presentation; full details not provided in filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318626,"accession_number":"0001609550-23-000008","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inspire Medical Q4 preliminary revenue ~$137.7M (+76% YoY); FY22 ~$407.7M (+75%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 preliminary revenue $137.5M-$137.9M, ~76% YoY increase.","Full-year 2022 revenue $407.5M-$407.9M, ~75% increase over FY 2021.","Activated 61 new U.S. implant centers in Q4 (total 905); added 16 sales territories (total 225).","European revenue growth driven by Germany, Switzerland, and the Netherlands.","Published inaugural Environmental, Social, and Governance (ESG) report."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":407856000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336861,"accession_number":"0001609550-22-000047","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inspire Medical Q3 revenue $109.2M (+77% YoY); raises FY2022 guidance to $384-388M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $109.2M (+77% YoY); raised FY2022 guidance to $384-388M from $354-362M.","Gross margin 81.9% (down from 86.0%) on inventory obsolescence and inflation; FY margin guidance maintained at 83-85%.","Net loss $16.8M ($0.60 diluted EPS) vs $10.3M ($0.38); cash $427.5M after $243.8M public offering.","Added 59 new U.S. centers (total 844) and 18 sales territories (total 209); launched Bluetooth remote and silicone leads.","European revenue down 14% on FX; France final pricing secured, reimbursement expected early 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":269956000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354247,"accession_number":"0001104659-22-094041","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2022-08-24T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Inspire Medical prepays all loans under Oxford Finance agreement, terminates Loan Agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Prepaid in full all outstanding loans under Loan & Security Agreement with Oxford Finance LLC on August 19, 2022.","Loan Agreement terminated (except indemnification/confidentiality) and all security interests in company assets released.","Prepayment fees of approximately $194,000 paid; no material relationships exist with Oxford Finance other than the loan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354246,"accession_number":"0001104659-22-091218","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inspire Medical Systems prices public offering of 1M shares at $215/share; net proceeds ~$243.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,000,000 shares at $215.00 per share; underwriter option for 150,000 shares exercised in full.","Net proceeds estimated at $243.8 million after underwriting discounts and expenses.","Plans to use net proceeds for sales/marketing expansion, reduce credit facility borrowings, R&D, and working capital.","Underwriting agreement with Goldman Sachs & Co. LLC; closing on August 15, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354245,"accession_number":"0001609550-22-000039","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inspire Medical Q2 revenue $91.4M (+73%), net loss $14.5M; FY guidance raised to $354M-$362M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $91.4M (+73% YoY); U.S. $87.9M (+78%), ex-U.S. $3.5M (-3% due to FX).","GAAP net loss $14.5M ($0.53 diluted EPS) vs $13.1M ($0.48) prior year; gross margin 84.5% (down from 85.8%).","FY2022 revenue guidance raised to $354M-$362M (from $336M-$344M); gross margin guidance lowered to 83%-85%.","Activated 52 new U.S. centers in Q2 (total 785); added 17 U.S. sales territories (total 191).","Received FDA approval for expanded full-body MRI; Breakthrough Device Designation for expanded AHI/BMI indication."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":160768000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354244,"accession_number":"0001609550-22-000034","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inspire Medical expands board to 11, appoints Burks and Sparks as directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 11 directors; Cynthia Burks and Dr. Charisse Sparks appointed effective July 28, 2022.","Burks, former CHRO at Genentech, appointed to Compensation Committee.","Dr. Sparks, CMO at AppliedVR and former VP at DePuy Synthes, appointed to Nominating & Governance Committee.","Each receives initial option award of $210,000 at $208.50/share; annual cash retainer of $45,000 plus committee fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372181,"accession_number":"0001609550-22-000030","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Inspire Medical amends loan agreement to set German subsidiary asset and income limits","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["German subsidiary GMBH exempted from subsidiary joinder requirements in loan agreement.","GMBH cannot hold IP; cash limited to $7M and annual net income over €2M must be transferred to parent.","Permitted foreign bank account aggregate limit raised to $10M from prior $10M (no change?) – actually increased from previous unspecified lower limit.","Quarterly investment cap of $5M in GMBH added as Permitted Investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-22T23:59:59+00:00|372181"}